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Strengths and limitations of this study
 ► Our methodology is based on the Cochrane 
Handbook for Systematic Reviews of Interventions, 
the PreferredReporting Items for Systematic Review 
and Meta- Analysis guideline and a systematic eight- 
step procedure for valid assessments of statistical 
and clinical significance.
 ► We systemically plan to assess risks of random er-
rors (‘play of chance’) and systematic errors (‘bias’).
 ► We have systematically predefined minimal import-
ant differences for all outcomes.
 ► The certainty of the evidence will be assessed us-
ing the Grading of Recommendations Assessment, 
Development and Evaluation approach.
AbStrACt
Introduction Pain is a frequent clinical symptom with 
significant impact on the patient’s well- being. Therefore, 
adequate pain management is of utmost importance. While 
cannabinoids have become a more popular alternative to 
traditional types of pain medication among patients, the 
quality of evidence supporting the use of cannabinoids 
has been questioned. The beneficial and harmful effects 
of cannabinoids in patients with pain is unknown. 
Accordingly, we aim to assess the efficacy, tolerability and 
safety of cannabinoids (herbal, plant- derived extracts and 
synthetic) compared with placebo or no intervention for 
any type of pain.
Methods and analyses We will conduct a systematic 
review of randomised clinical trials with meta- analysis 
and Trial Sequential Analysis to assess the beneficial and 
harmful effects of cannabinoids in any dose, formulation 
and duration. We will accept placebo or no treatment as 
control interventions. We will include participants with any 
type of pain (acute and chronic pain, cancer- related pain, 
headache, neuropathic pain or any other types of pain). We 
will systematically search The Cochrane Library, MEDLINE, 
Embase, Science Citation Index and BIOSIS for relevant 
literature. We will follow the recommendations by Cochrane 
and the Preferred Reporting Items for Systematic Review 
and Meta- Analysis statement. The risk of systematic errors 
(bias) and random errors (play of chance) will be assessed. 
The overall certainty of evidence will be evaluated using the 
Grading of Recommendations Assessment, Development and 
Evaluation approach.
Ethics and dissemination Ethical approval is not a 
requirement since no primary data will be collected. The 
findings of this systematic review will be submitted for 
peer- reviewed publication and disseminated in national 
and international conferences.
Discussion Although cannabinoids are now being used to 
manage different pain conditions, the evidence for the clinical 
effects are unclear. The present review will systematically 
assess the current evidence for the benefits and harms of 
cannabinoids to inform practice and future research.
IntroDuCtIon
Pain is the most commonly reported 
symptom in the general population and in a 
medical setting.1–3 Persistent pain is a major 
international health problem,4 prompting the 
WHO to endorse a global campaign against 
pain.5 Pain is the leading reason for use of 
alternative medicines (ie, acupuncture, etc).6 
Pain has been associated with a low degree 
of health- related quality of life and may lead 
to psychosocial distress, insomnia and depres-
sive symptoms.7–15 Pain is also among the most 
common reasons for temporary or permanent 
work disability.16 Pain is always subjective and 
may be defined as ‘an unpleasant sensory and 
emotional experience associated with actual or 
potential tissue damage’.17
Cannabinoids have emerged as a poten-
tial alternative to other painkillers for the 
treatment of intractable pain.18 Before the 
healthcare systems globally can endorse the 
applicability of cannabinoids for pain, the 
potential short- time and long- term benefits 
and harms with use of cannabinoids must be 
investigated. This is of utmost importance 
because patients who consume cannabinoids 
to alleviate their chronic pain will most likely 
need to consume cannabinoids for the rest of 
their lifespan.
Protected by copyright.
 o
n
 April 23, 2020 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031574 on 31 October 2019. Downloaded from 
2 Barakji JA, et al. BMJ Open 2019;9:e031574. doi:10.1136/bmjopen-2019-031574
Open access 
DESCrIptIon of pAIn
Pain may be caused by or be related to different clinical 
disorders and classified according to several different 
characteristics.19–22 Below, we describe shortly some of 
these classifications.
Acute and chronic pain
Pain may be classified as ‘acute pain’ or ‘chronic pain’.
 ► Acute pain usually has a well- defined onset and most 
often a readily identifiable cause (ie, surgery, etc). 
Acute pain is expected to run its course in a short 
time frame and management typically focuses on 
symptomatic relief until this happens.23 Acute pain is 
a common symptom, affecting between 37% to 84% 
of hospitalised patients.24
 ► Chronic pain is often characterised by an ill- defined 
onset and a prolonged, fluctuating course.23 Chronic 
pain often persists past normal healing time and 
hence lacks the acute warning function of physiolog-
ical nociception.25 Pain is usually regarded as chronic 
when it lasts or recurs for more than 3 to 6 months.17 26 
Chronic pain is a frequent condition, affecting an esti-
mated 20% of people worldwide27–30 and accounting 
for 15% to 20% of physician visits according to Euro-
pean observational studies.31 32
Cancer-related pain
Pain may also be classified based on whether it is cancer- 
related or non- cancer- related. Cancer- related pain is pain 
caused by the cancer itself (primary tumour and metas-
tases) or its treatment (ie, radiation therapy, etc).23 33
postoperative pain
Postoperative pain includes pain from inflammation 
caused by tissue trauma (ie, surgical incision, dissection, 
burns, etc) or direct nerve injury (eg, nerve transection, 
stretching or compression).34 Inflammation results in 
activation and sensitisation of nociceptive pain pathways, 
resulting in primary and secondary hyperalgesia and 
central sensitisation, which is characterised by clinically 
increased pain, allodynia and increased sensitivity from 
surrounding non- damaged anatomical areas.35
other types of pain
Pain in one or more anatomical regions where the aeti-
ology is unknown is defined as idiopathic pain.36 Examples 
of idiopathic pain are chronic widespread pain, fibromy-
algia, irritable bowel syndrome and back pain that is not 
diagnosed as musculoskeletal or as neuropathic pain.33
pain types defined according to specific mechanism causing 
the pain
Somatic nociceptive pain
Nociceptive pain is the most frequent type of pain. It 
results from activity in neural pathways caused by actual 
tissue damage or potentially tissue- damaging stimuli31 37 
originating from somatic nociceptors from skin, bone, 
joints or muscles.38
Visceral nociceptive pain
The visceral nociceptive pain is pain resulting from viscera 
in the thoracic, pelvis or abdominal organs.39–41 Visceral 
pain is diffuse, less distinctive and difficult to localise41 
and is often characterised by referred visceral pain.42
Neuropathic pain
The 2011 International Association for the Study of Pain 
definition of neuropathic pain is ‘pain caused by a lesion 
or disease of the somatosensory system’.43 Neuropathic 
pain may be classified as central neuropathic pain or 
peripheral neuropathic pain. Central neuropathic pain 
conditions are mainly attributed to multiple sclerosis 
and poststroke pain,44 while peripheral neuropathic 
pain is largely due to postherpetic neuralgia and diabetic 
neuropathy.45
DESCrIptIon of thE IntErvEntIon
Cannabis (also called marijuana) is the most common 
illegally used psychoactive substance worldwide.46 Canna-
binoids refer to a heteromorphic group of molecules that 
demonstrate activity on cannabinoid receptors.47 Canna-
binoids may be classified into three groups: (1) endo-
cannabinoids, (2) phytocannabinoids and (3) synthetic 
cannabinoids.47
Endocannabinoids
Endocannabinoids are characterised by being the endog-
enously generated cannabinoids.48 The primary types of 
endocannabinoids are the lipid endocannabinoid arachi-
donoyl ethanolamide (named anandamide)49 and the 
endocannabinoid 2- arachidonoylglycerol.50 51
phytocannabinoids
Phytocannabinoids are cannabinoids found in the 
cannabis plant.52 The best characterised phytocannabi-
noids are the psychotropic tetrahydrocannabinol (THC) 
and the primarily anti- inflammatory cannabidiol.53 
Nabiximols (marketed as Sativex) is a sublingually admin-
istered oromucosal spray based on a mixture of tetrahy-
drocannabinol and cannabidiol.54
Synthetic cannabinoids
Synthetic cannabinoids are analogues of the cannabinoids 
found in natural marijuana that are chemically synthesised. 
The most commonly prescribed cannabinoid- based medi-
cines are the synthetic cannabinoids dronabinol (marketed 
as Marinol) and nabilone (marketed as Cesamet).54
EnDoCAnnAbInoID SyStEM
All cannabinoids act on cannabinoid receptors. These 
cannabinoid receptors are located throughout the body 
but are mostly located in the brain.55 The cannabinoid 
receptors and endocannabinoids (see paragraph above) 
are together named the endocannabinoid system.56
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Cannabinoid receptors
There are two types of cannabinoid receptors, type I and 
type II.57 Cannabinoid receptor type I are most abundant 
in the central nervous system, especially in areas promoting 
nociception, short- term memory and in the basal ganglia, 
but are also found in the peripheral nerves, uterus, testis 
and bones.57 Tetrahydrocannabinol activates cannabinoid 
type I receptors in the dopaminergic mesolimbic brain 
circuit, resulting in enhanced release of dopamine.58 Such 
activation of the so- called ‘brain reward system’ is hypoth-
esised to mediate the positive reinforcing and rewarding 
effects of almost all drugs of abuse.58
In contrast, cannabinoid receptor type II, is mostly found 
in the periphery, often in conjunction with immune cells, 
but may appear in the central nervous system particularly 
under conditions of inflammation in association with 
microcytes.57 The physiological responses that result from 
cannabinoid receptor activation are euphoria, psychosis, 
impaired memory and cognition, reduced locomotor 
function, increased appetite, as well as anti- emetic, pain- 
relieving, anti- spasticity and sleep- promoting effects.59
Administration of cannabinoids
Cannabis is most commonly consumed via smoked, 
inhaled vapour or oral routes of administration.60 
Vaporising cannabis (‘vaping’) heats the material without 
burning which theoretically minimises potential carcino-
gens compared with smoking and may produce less respi-
ratory irritation.61 62 Sublingual administration is used for 
some medical cannabis preparations (ie, nabiximols, etc).
Why It IS IMportAnt to Do thIS rEvIEW
We identified 10 previous reviews with meta- analyses 
assessing the effects of cannabinoids on different types 
of pain.63–72 Bearing in mind that some of the previous 
reviews investigated more than one type of pain, eight 
reviews assessed the effects of different cannabinoids on 
neuropathic pain63–69 72; four reviews assessed the effects of 
different cannabinoids on nociceptive pain (ie, rheumatoid 
arthritis, etc)63 64 67 68; three reviews assessed the effects of 
different cannabinoids on cancer- related pain63 67 68; four 
reviews assessed the effects of different cannabinoids on 
fibromyalgia- related pain63 64 67 71 and three reviews assessed 
the effects of different cannabinoids on postoperative 
pain.63 68 70 All the previous reviews included randomised 
clinical trials, but only 2 of the 10 reviews systematically 
assessed the risk of bias in the trials,65 72 and none of the 
previous reviews took into account the risks of random 
errors.63–72 Only 2 out of the 10 reviews used predefined 
Cochrane methodology71 72 and only 4 reviews used the 
Gradingof Recommendations Assessment, Development 
and Evaluation (GRADE) approach.65 70–72
Most of the reviews concluded that the assessed canna-
binoids were effective against pain.63–67 69 72 In table 1 
(online supplementary file 1), we have summarised the 
results and conclusions of the previous reviews. Five of 
the reviews reported serious adverse events (ie, agitation, 
impaired memory, abuse, dissociation, acute psychosis, 
death, etc).63 65–67 72 The reviews also showed that the most 
commonly reported adverse events were sedation, dizzi-
ness, dry mouth, increased appetite, somnolence, confu-
sion, nausea and disturbances in concentration.63–66 68 69 71 72
A correlation between psychiatric disorders (schizo-
phrenia, psychosis, etc) and increased cannabinoid 
consumption has previously been hypothesised.73–79 
Di Forti et al recently conducted a study indicating that 
daily cannabis use was associated with increased odds of 
psychotic disorders compared with never users (adjusted 
OR 3.2, 95% CI 2.2 to 4.1), increasing to nearly five- times 
increased odds for daily use of high- potency (THC ≥10%) 
types of cannabis (adjusted OR 4.8, 95% CI 2.5 to 6.3).80
Compared with previous systematic reviews on cannabi-
noids, we want to assess the effects of all types of canna-
binoid versus placebo or no intervention for all different 
forms of pain. Depending on the data results provided 
by the included trials this could increase the power and 
precision of the overall analysis and make it possible to 
conduct subgroup analyses and sensitivity analyses that 
may identify pain areas where cannabinoid could be 
especially beneficial and cause the least harms. In addi-
tion, we will implement a minimal clinically important 
threshold regarding analgesic efficacy based on previously 
conducted methodological studies which ensures that 
analgesic efficacy is of a firm significance before accep-
tance. Finally, by instigating all types of cannabinoids 
treated for any type of pain this systematic review will aid 
trialist in optimising the design of future randomised clin-
ical trials by illuminating any research pitfalls of all previ-
ously conducted randomised clinical trials on this topic.
objective
The objective of our systematic review is to assess the anal-
gesic efficacy and adverse events encumbered with the 
use of cannabinoids compared with placebo or no inter-
vention in participants with any type of pain (acute and 
chronic pain, cancer- related pain, headache, neuropathic 
pain or any other types of pain). A secondary objective of 
this systematic review is to assess the impact of cannabi-
noid use on the quality of sleep and quality of life which 
is especially decreased in participants with chronic pain.
MEthoDS
This systematic review protocol has been developed based 
on Preferred Reporting Items for Systematic Reviews 
and Meta- Analysis Protocols (PRISMA- P) guidelines for 
reporting systematic reviews evaluating healthcare inter-
ventions.81 82 A PRISMA- P checklist file is attached (online 
supplementary file 2).
CrItErIA for ConSIDErIng StuDIES for thIS rEvIEW
type of studies
Randomised clinical trials irrespective of trial design, 
setting, publication status, publication year and language. 
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If we identify quasi- randomised studies and observational 
studies during our searches for randomised clinical trials, 
we will only include their reporting on harms in a narra-
tive way. By not systematically searching for all observa-
tional studies on harm, we run the risk of putting more 
focus on benefit than harm. We are aware that this is a 
limitation of our review.
types of participants
Participants with any type of pain, that is, acute and 
chronic pain, cancer- related pain, headache, neuro-
pathic pain or any other types of pain (as defined by the 
trialists). Participants will be included irrespective of age, 
sex and comorbidities.
types of interventions
Experimental intervention
Any type of cannabinoids such as: herbal cannabis 
(hashish, marijuana), plant‐based extracts (ie, nabixi-
mols, etc) or synthetic cannabinoids (ie, cannabidiol, 
dronabinol, levonantradol, nabilone, etc). We will accept 
cannabinoids at any dose, by any route, administered for 
the relief of pain.
Control intervention
Placebo or no intervention.
Co-interventions
We will accept any co- intervention but only if this co- inter-
vention is planned to be delivered similarly in both inter-
vention groups. If this plan is not followed, then these trials 
will be assessed as a subgroup due to potential confounding.
types of outcome measures
Primary outcomes
 ► All- cause mortality.
 ► Pain assessment on Visual Analogue Scale (VAS) or 
Numerical Rating Scale (NRS).
 ► Proportion of participants with a serious adverse event 
defined as any untoward medical occurrence that 
resulted in death; was life threatening; was persistent 
or led to significant disability, nephrotoxicity, superin-
fection, need for respiratory support, need for circu-
latory support or prolonged hospitalisation.83 As we 
expect the trialists’ reporting of serious adverse events 
to be heterogeneous and not strictly according to the 
International Conference on Harmonisation - Good 
Clinical Practice (ICH- GCP) recommendations, we 
will include the event as a serious adverse if the trial-
ists either: (1) use the term 'serious adverse event' but 
not refer to ICH- GCP, or (2) report the proportion of 
participants with an event we consider fulfils the ICH- 
GCP definition. If several of such events are reported 
then we will choose the highest proportion reported 
in each trial.
 ► Quality of life measured on any valid continuous scale.
Secondary outcomes
 ► Dependence (as defined by trialists).
 ► Psychosis (as defined by trialists).
 ► Proportion of participants with one or more adverse 
event not considered to be serious.
 ► Quality of sleep measured on any valid continuous 
scale.
Exploratory outcomes
 ► Each serious adverse event separately.
 ► Each adverse event not considered serious separately.
 ► Twenty- four hour morphine consumption (as defined 
by trialists).
 ► Physical function (as defined by trialists).
 ► Depressive symptoms (eg, Hamilton Depression 
Rating Scale).
We will for all outcomes use the trial results reported at 
maximal follow- up except for acute pain. For acute pain, 
we will use the trials’ results reported at the time point 
closest to 24 hours after the intervention is given.
patient and public involvement
We have had email correspondence with several relevant 
patient associations in Denmark to select the most patient- 
relevant outcomes. The patient associations we have been 
in contact with included: The Danish Diabetes Association, 
Steno Diabetes Centre Copenhagen, The Danish Rheuma-
tism Association, The Danish Multiple Sclerosis Society and 
Danish Cancer Society. Initially we presented our potential 
outcomes for the patient associations and requested for 
their opinion. We had not included quality of sleep as an 
outcome, however, this was mentioned by almost all patient 
associations and it was included as a crucial secondary 
outcome. All- cause mortality was questioned by one of the 
patient associations, however, we want to keep this outcome 
because of potential increased risk of both acute coronary 
syndrome and chronic cardiovascular disease associated 
with cannabis use.84
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of 
Controlled Trials (CENTRAL), Medical Literature Anal-
ysis and Retrieval System Online (MEDLINE), Excerpta 
Medica database (Embase), Latin American and Carib-
bean Health Sciences Literature (LILACS), Science Cita-
tion Index Expanded on Web of Science and BIOSIS in 
order to identify relevant trials. The preliminary search 
strategy for CENTRAL, MEDLINE (Ovid), Embase 
(Ovid), LILACS, Web of Science and BIOSIS is given in 
online supplementary file 3.
We will search all databases from their inception to the 
1st of October 2019.
Searching other resources
The reference lists of relevant publications will be checked 
for any unidentified randomised trials. We will contact 
authors of included studies, and major pharmaceutical 
companies, by email asking for unpublished randomised 
trials. Further, we will search for ongoing trials on:
 ►  ClinicalTrials. gov ( www. clinicaltrials. gov)
Protected by copyright.
 o
n
 April 23, 2020 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031574 on 31 October 2019. Downloaded from 
5Barakji JA, et al. BMJ Open 2019;9:e031574. doi:10.1136/bmjopen-2019-031574
Open access
 ► Google Scholar (https:// scholar. google. dk/)
 ► The Turning Research into Practice (TRIP) Database 
(https://www. tripdatabase. com/)
 ► European Medicines Agency (EMA) (http:// www. 
ema. europa. eu/ ema/)
 ► United States Food and Drug Administration (FDA) ( 
www. fda. gov)
 ► China Food and Drug Administration (http:// eng. 
sfda. gov. cn/ WS03/ CL0755/)
 ► Medicines and Healthcare products Regulatory 
Agency (https://www. gov. uk/ government/ organisa-
tions/ medicines- and- healthcare- products- regulatory- 
agency)
 ► The WHO International Clinical Trials Registry 
Platform search portal (http:// apps. who. int/ 
trialsearch/)
We will also consider relevant for the review unpub-
lished and grey literature trials, if we identify such trials.
Data collection and analysis
We will perform the review following the recommenda-
tions of Cochrane.85 The analyses will be performed using 
Review Manager 586 and Trial Sequential Analysis.87 In 
case of Review Manager statistical software is not being 
sufficient, we will use Stata 15.88
Selection of studies
Two authors (JB, SKK) will independently screen titles 
and abstracts. We will retrieve all relevant full- text study 
reports/publications, and four review authors (JB, SKK, 
JRF, MM) will independently screen the full texts and 
identify and record reasons for exclusion of the ineli-
gible studies. We will resolve any disagreement through 
discussion or, if required, we will consult a fifth author 
(JCJ). Trial selection will be displayed in an adapted flow 
diagram as per the Preferred Reporting Items for System-
atic Reviews and Meta- Analyses statement.89
Data extraction and management
Four authors (JB, SKK, JRF, MM) will in pairs extract data 
independently from included trials. Disagreements will 
be resolved by discussion with a fifth author (JCJ). We will 
assess duplicate publications and companion papers of 
a trial together to evaluate all available data simultane-
ously (maximise data extraction, correct bias assessment). 
We will contact the trial authors by email to specify any 
additional data, which may not have been reported suffi-
ciently or at all in the publication.
Trial characteristics
Bias risk components (as defined below), trial design 
(parallel, factorial or crossover), number of intervention 
arms, length of follow- up, estimation of sample size, inclu-
sion and exclusion criteria.
Participant characteristics and diagnosis
Number of randomised participants, number of analysed 
participants, number of participants lost to follow- up/
withdrawals/crossover, compliance with medication, age 
range (mean or median) and sex ratio, type of pain (acute 
and chronic pain, cancer- related pain, headache, neuro-
pathic pain or any other types of pain), baseline pain score, 
drug and dosing regimen, study design (placebo or active 
control), study duration and follow‐up, analgesic outcome 
measures and results, adverse events (participants experi-
encing any adverse event, or serious adverse event).
Co-intervention characteristics
Type of co- intervention, dose of co- intervention, duration 
of co- intervention and mode of administration.
Outcomes
All outcomes listed above will be extracted from each 
randomised clinical trial, and we will identify if outcomes 
are incomplete or selectively reported according to the 
criteria described later in ‘incomplete outcome data’ bias 
domain and ‘selective outcome reporting’ bias domain.
Notes
Funding of the trial and notable conflicts of interest of 
trial authors will be extracted, if available.
We will note in the ‘Characteristics of included studies’ 
table if outcome data were not reported in a usable 
way. Four review authors (JB, SKK, JRF, MM) will inde-
pendently transfer data into the Review Manager file.86 
Disagreements will be resolved through discussion or, if 
required, we will consult with a fifth author (JCJ).
Assessment of risk of bias in included studies
We will use the instructions given in the Cochrane Hand-
book for Systematic Reviews of Interventions85 in our evalu-
ation of the methodology and hence the risk of bias of the 
included trials. We will evaluate the methodology in respect 
of:
 ► Random sequence generation.
 ► Allocation concealment.
 ► Blinding of participants and treatment providers.
 ► Blinding of outcome assessment.
 ► Incomplete outcome data.
 ► Selective outcome reporting.
 ► For- profit bias.
 ► Overall risk of bias.
These components enable classification of randomised 
trials as being at low risk of bias and at high risk of bias. 
The latter trials tend to overestimate positive intervention 
effects and underestimate negative effects.90–96
We will classify the trials according to the following 
criteria.
Random sequence generation
 ► Low risk: If sequence generation was achieved using 
computer random number generator or a random 
number table. Drawing lots, tossing a coin, shuffling 
cards and throwing dice were also considered adequate 
if performed by an independent adjudicator.
 ► Unclear risk: If the method of randomisation was not 
specified, but the trial was still presented as being 
randomised.
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 ► High risk: If the method of sequence generation was 
inadequate for example, alternate medical record 
numbers or other non- random sequence generation.
Allocation concealment
 ► Low risk: If the allocation of patients was performed by 
a central independent unit, on- site locked computer, 
identical- looking numbered sealed envelopes, drug 
bottles or containers prepared by an independent 
pharmacist or investigator.
 ► Uncertain risk: If the trial was classified as randomised 
but the allocation concealment process was not 
described.
 ► High risk: If the allocation sequence was familiar to 
the investigators who assigned participants.
Blinding of participants and treatment providers
 ► Low risk: If the participants and the treatment 
providers were blinded to intervention allocation and 
this was described.
 ► Uncertain risk: If the procedure of blinding was insuf-
ficiently described.
 ► High risk: If blinding of participants and the treat-
ment providers was not performed.
Blinding of outcome assessment
 ► Low risk of bias: If it was mentioned that outcome 
assessors were blinded and this was described.
 ► Uncertain risk of bias: If it was not mentioned if the 
outcome assessors in the trial were blinded or the 
extent of blinding was insufficiently described.
 ► High risk of bias: If no blinding or incomplete 
blinding of outcome assessors was performed.
Incomplete outcome data
 ► Low risk of bias: If missing data were unlikely to 
make treatment effects depart from plausible values. 
This could be either (1) there were no dropouts or 
withdrawals for all outcomes or (2) the numbers 
and reasons for the withdrawals and dropouts for all 
outcomes were clearly stated and could be described 
as being similar to both groups. Generally, the trial 
is judged as at a low risk of bias due to incomplete 
outcome data if dropouts are less than 5%. However, 
the 5% cut- off is not definitive.
 ► Uncertain risk of bias: If there was insufficient infor-
mation to assess whether missing data were likely to 
induce bias on the results.
 ► High risk of bias: If the results were likely to be biassed 
due to missing data either because the pattern of 
dropouts could be described as being different in the 
two intervention groups or the trial used improper 
methods in dealing with the missing data (ie, last 
observation carried forward, etc).
Selective outcome reporting
 ► Low risk of bias: If a protocol was published before 
or at the time the trial was begun, and the outcomes 
specified in the protocol were reported on. If there is 
no protocol or the protocol was published after the 
trial has begun, reporting pain assessment on VAS or 
NRS and serious adverse events will grant the trial a 
grade of low risk of bias.
 ► Uncertain risk of bias: If no protocol was published 
and the outcome pain assessment on VAS or NRS and 
serious adverse events were not reported on.
 ► High risk of bias: If the outcomes in the protocol were 
not reported on.
For-profit bias
 ► Low risk of bias: If the trial appeared to be free of 
other components of for- profit bias.
 ► Unclear risk of bias: If it was unclear whether the trial 
was free of for- profit bias.
 ► High risk of bias: If there was a high risk of for- profit 
bias.
Overall risk of bias
 ► Low risk of bias: The trial will be classified at overall 
‘low risk of bias’ only if all of the bias domains 
described in the above paragraphs are classified at 
‘low risk of bias’.
 ► High risk of bias: The trial will be classified at ‘high 
risk of bias’ if any of the bias risk domains described 
in the above are classified at ‘unclear’ or ‘high risk of 
bias’.
We will assess the domains ‘blinding of outcome assess-
ment’, ‘incomplete outcome data’ and ‘selective outcome 
reporting’ for each outcome result. Thus, we can assess the 
bias risk for each outcome assessed in addition to each trial. 
Our primary conclusions will be based on the results of our 
primary outcome results at overall low risk of bias. Both our 
primary and secondary analyses will be presented in the 
summary of findings tables.
Differences between the protocol and the review
We will conduct the review according to this published 
protocol and report any deviations from it in the ‘Differ-
ences between the protocol and the review’ section of the 
systematic review.
Measures of treatment effect
Dichotomous outcomes
We will calculate risk ratios with 95% CI for dichotomous 
outcomes, as well as the Trial Sequential Analysis- adjusted 
CIs (see below).
Continuous outcomes
We will calculate the mean differences and the stan-
dardised mean difference with 95% CI for continuous 
outcomes, as well as the Trial Sequential Analysis- adjusted 
CIs (see below).
Dealing with missing data
We will, as first option, contact all trial authors to obtain 
any relevant missing data (ie, for data extraction and for 
assessment of risk of bias, as specified above).
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Dichotomous outcomes
We will not impute missing values for any outcomes in 
our primary analysis. In two of our sensitivity analyses (see 
paragraph below), we will impute data.
Continuous outcomes
We will primarily analyse scores assessed at single time 
points. If only changes from baseline scores are reported, 
we will analyse the results together with follow- up scores.85 
If SDs are not reported, we will calculate the SDs using 
trial data, if possible. We will not use intention- to- treat 
data if the original report did not contain such data. We 
will not impute missing values for any outcomes in our 
primary analysis. In our sensitivity analysis (see paragraph 
below) for continuous outcomes, we will impute data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually assess 
any sign of heterogeneity. We will secondly assess the 
presence of statistical heterogeneity by X2 test (threshold 
p<0.10) and measure the quantities of heterogeneity by 
the I2 statistic.97 98 We will investigate for heterogeneity 
through subgroup analyses. Ultimately, we may decide 
that a meta- analysis should be avoided.85
Assessment of reporting biases
We will use a funnel plot to assess reporting bias if 10 or 
more trials are included. We will visually inspect funnel 
plots to assess the risk of bias. We are aware of the limita-
tions of a funnel plot (ie, a funnel plot assesses bias due to 
small sample size, etc). From this information, we assess 
possible reporting bias. For dichotomous outcomes, we 
will test asymmetry with the Harbord test99 if τ2 is less than 
0.1 and with the Rücker test if τ2 is more than 0.1. For 
continuous outcomes, we will use the regression asym-
metry test100 and the adjusted rank correlation.101
Unit of analysis issues
We will only include randomised clinical trials. For trials 
using crossover design, only data from the first period will 
be included.85 102 There will therefore not be any unit of 
analysis issues.
Minimal important difference
In clinical intervention research it is of utmost impor-
tance always to define minimal important differences and 
to define thresholds for clinical significance.103 If a large 
number of trial participants are randomised, small and clin-
ically irrelevant intervention effects may lead to statistically 
significant results and rejection of the null hypothesis.104 
Jaeschke et al defined the minimal important difference as 
‘the smallest difference in score in the domain of interest 
which patients perceive as beneficial’.105
Estimations of minimal important differences should be 
used as arbitrary strict precise thresholds. However, to avoid 
erroneous conclusions minimal important differences 
need to be estimated and predefined when assessing the 
effects of interventions for pain. Olsen et al have conducted 
two systematic reviews on this matter in order to gather the 
evidence and present an estimate of the minimal important 
difference.106 107 Olsen et al conducted a systematic review 
on the minimal important difference in patients with acute 
pain and concluded that the median of the studies’ results 
was 17 mm on VAS (IQR 14 mm to 23 mm).106 Another 
systematic review conducted by Olsen et al was on the 
minimal important difference in patients with chronic pain 
and the results showed a median of 23 mm on VAS (IQR 12 
mm to 39 mm) when using the within- patient anchor- based 
method, while the median in studies using the sensitivity- 
based and specificity- based method was 20 mm on VAS 
(IQR 15 mm to 30 mm).107 We have described detailed 
considerations about minimal important differences in 
online supplementary appendix 4.
Based on the previously conducted systematic reviews 
we will choose at minimal important difference equivalent 
to 10 mm or 1 point on the visual analogue scale and the 
numerical rating scale, respectively, regarding an analgesic 
effect.
Data synthesis
Meta-analysis
We will undertake this meta- analysis according to the 
recommendations stated in the Cochrane Handbook 
for Systematic Reviews of Interventions,85 Keus et al108 
and the eight- step assessment suggested by Jakobsen et 
al.103 We will use the statistical software Review Manager 
5.386 provided by Cochrane to analyse data. We will assess 
our intervention effects with both random- effects meta- 
analyses109 and fixed- effect meta- analyses.110 We will use 
the more conservative point estimate of the two.103 The 
more conservative point estimate is the estimate closest to 
zero effect. If the two estimates are similar, we will use the 
estimate with the highest p value.103 We use four primary 
and four secondary outcomes, and therefore, we will 
consider a p value of 0.02 as the threshold for statistical 
significance.103 111 We will investigate for heterogeneity 
through subgroup analyses. Ultimately, we may decide 
that a meta- analysis should be avoided.85 We will use the 
eight- step procedure to assess if the thresholds for statis-
tical and clinical significance are crossed.103 Our primary 
conclusion will be based on results with low risk of bias.103
Where multiple trial intervention groups are reported 
in a single trial, we will include only the relevant groups. 
If two comparisons are combined in the same meta- 
analysis, we will halve the control group to avoid double 
counting.85 Trials with a factorial design will be included.
If quantitative synthesis is not appropriate, we will 
report the results in a narrative way.
Trial sequential analysis
Traditional meta- analysis runs the risk of random errors 
due to sparse data and repetitive testing of accumulating 
data when updating reviews. We wish to control the risks 
of type I errors and type II errors. We will therefore 
perform Trial Sequential Analysis on the outcomes, in 
order to calculate the required information size (that 
is the number of participants needed in a meta- analysis 
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to detect or reject a certain intervention effect) and the 
cumulative Z- curve’s breach of relevant trial sequential 
monitoring boundaries.87 112–120 A more detailed descrip-
tion of Trial Sequential Analysis can be found in the Trial 
Sequential Analysis manual113 and at http://www. ctu. dk/ 
tsa/. For dichotomous outcomes, we will estimate the 
required information size based on the observed propor-
tion of patients with an outcome in the control group 
(the cumulative proportion of patients with an event in 
the control groups relative to all patients in the control 
groups), a relative risk reduction of 20%, an alpha of 
2.0% for our primary and secondary outcomes, a beta of 
10% and diversity as suggested by the trials in the meta- 
analysis. For the outcome ‘pain assessment on visual 
analogue scale or numerical rating scale’, we will use a 
minimal important difference estimate based on previ-
ously conducted systematic reviews.106 107 We will accept 
an analgesic effect equivalent to 10 mm or 1 point on 
the visual analogue scale and the numerical rating scale, 
respectively, or a consumption of at least 5 mg morphine.
For all remaining continuous outcome, we will in the 
Trial Sequential Analysis use the observed SD, a mean 
difference of the observed SD/2, an alpha of 2.0% for 
our primary and secondary outcomes and a beta of 10%.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis
We will perform the following subgroup analysis when 
analysing the primary outcomes (all- cause mortality, pain 
assessment on VAS or NRS, serious adverse event and 
quality of life).
 ► Trials at high risk of bias compared with trials at low 
risk of bias.
 ► Trials at risk of vested interests compared with trial 
with no risk of vested interests.
 ► Trials compared according to type of pain (acute 
pain, chronic pain and cancer pain).
 ► Trials compared according to type of chronic pain.
 ► Trials compared according to type of cannabinoids 
used.
We will use the formal test for subgroup interactions in 
Review Manager.86
Sensitivity analysis
To assess the potential impact of the missing data for 
dichotomous outcomes, we will perform the two following 
sensitivity analyses on both the primary and secondary 
outcomes.
 ► ‘Best- worst- case’ scenario: We will assume that all 
participants lost to follow- up in the cannabinoid 
intervention group have survived, and had no serious 
adverse event, and that all those participants lost to 
follow- up in the placebo group have not survived, and 
had a serious adverse event.
 ► ‘Worst- best- case’ scenario: We will assume that all 
participants lost to follow- up in the cannabinoid inter-
vention group have not survived, and had a serious 
adverse event, and that all those participants lost to 
follow- up in the placebo group have survived, and had 
no serious adverse event.
We will present results of both scenarios in our review.
For all continuous outcome when analysing a ‘benefi-
cial outcome’ will be the group mean plus two SDs (we 
will secondly use one SD in another sensitivity analysis) 
of the group mean and a ‘harmful outcome’ will be the 
group mean minus two SDs (we will seconds use one 
SD in another sensitivity analysis) of the group mean.103
To assess the potential impact of missing SDs for contin-
uous outcomes, we will perform the following sensitivity 
analysis.
 ► Where SDs are missing and it is not possible to calcu-
late them, we will impute SDs from trials with similar 
populations and low risk of bias. If we find no such 
trials, we will impute SDs from trials with a similar 
population. As the final option, we will impute SDs 
from all trials.
We will present results of this scenario in our review. 
Other post hoc sensitivity analyses might be warranted if 
unexpected clinical or statistical heterogeneity is identi-
fied during the analysis of the review results.103
Summary of findings
We will create a ‘Summary of Findings’ table using 
each of the primary outcomes (all- cause mortality, pain 
assessment on VAS or NRS, serious adverse event and 
quality of life). We will use the five GRADE consider-
ations (bias risk of the trials, consistency of effect, impre-
cision, indirectness and publication bias) to assess the 
quality of a body of evidence as it relates to the studies 
which contribute data to the meta- analyses for the 
prespecified outcomes.103 121–123 We will use methods 
and recommendations described in Chapter 8 (Section 
8.5) and Chapter 12 of the Cochrane Handbook for 
Systematic Reviews of Interventions85 using GRADEpro 
software. We will justify all decisions to downgrade the 
quality of studies using footnotes, and we will make 
comments to aid the reader’s understanding of the 
review where necessary. First, we will present our results 
in the ‘Summary of Findings’ table based on the results 
from the trials with low risk of bias, and second, we will 
present the results based on all trials.
Ethics and dissemination
Ethical approval is not a requirement since no primary 
data will be collected. The findings of this systematic 
review will be submitted for peer- reviewed publication 
and disseminated in national and international confer-
ences and is expected to inform healthcare workers and 
providers about the occurrence of serious and non- serious 
adverse events following cannabinoid consumption. It is 
expected that the findings of this systematic review will 
identify some research gaps for future trials.
DISCuSSIon
This protocol aims at investigating the beneficial and 
harmful effects of cannabinoids in patients with any 
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type of pain condition. The outcomes will be all- cause 
mortality, pain assessment on VAS or NRS, serious adverse 
events, quality of life, dependence, psychosis, non- serious 
adverse events and sleep quality.
This protocol has several strengths. The predefined 
methodology is based on the Cochrane Handbook for 
Systematic Reviews of Interventions,85 the eight- step 
assessment suggested by Jakobsen et al,103 Trial Sequen-
tial Analysis84 and GRADE assessment.121–123 Hence, this 
protocol takes both the risk of random error and the 
risk of systematic error into account. We predefined 
evidence- based estimations of minimal important 
differences which will limit the risk of focusing on 
statistically significant results with questionable clin-
ical importance. This threshold of minimal important 
difference is based on the estimations of several previ-
ously conducted studies and reviews.106 107 Moreover, we 
are including all types of cannabinoids and all types of 
pain which will increase the statistical power and make 
it possible to perform essential subgroup analyses. We 
have been in contact with several relevant patient asso-
ciations which has assisted us in choosing the most clin-
ically relevant outcomes.
Our protocol also has several limitations. One of the 
potential limitations is that we include participants with all 
types of pain; cannabinoids might have different effects on 
different types of pain. It might, for example, be problem-
atic to combine trials assessing the effects of cannabinoids 
on acute pain and chronic pain because of different under-
lying pathophysiological mechanisms.124 On the other hand, 
the effects of cannabinoids on acute pain and chronic pain 
might be comparable and hence it might be valid to combine 
trials assessing the effects of cannabinoids on acute pain 
and chronic pain in meta- analysis, which would increase 
the statistical power. The results of the subgroup analysis 
comparing trials including participants with acute pain to 
participants with chronic pain will therefore be highlighted 
when reporting our review results. Moreover, we only intend 
to assess cannabinoids versus placebo or versus no interven-
tion. Further systematic reviews with meta- analyses and Trial 
Sequential Analyses need to assess the benefits and harms of 
cannabinoids versus other pain killers, provided that cannabi-
noids show more benefit than harm in the present systematic 
review.
Furthermore, more than one active cannabinoid agent 
is often combined in the different intervention options 
provided to the patients with a pain condition, thereby 
making difficult to explore the analgesic effect and 
adverse event associated with a single cannabinoid agent. 
Hence, if we show a difference between the intervention 
options, it will be difficult to conclude what exactly caused 
the difference in effect. To minimise these limitations, we 
have planned a careful assessment of statistical and clin-
ical heterogeneity as well as several subgroup analyses and 
sensitivity analyses. Another limitation is the large number 
of comparisons which increase the risk of type 1 error. We 
have adjusted our thresholds for significance according 
to the number of primary outcomes, but, as mentioned, 
we have also included multiple subgroup analyses. This 
large risk of type 1 error will be taken into account when 
interpreting the review results.
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